Table 2.

Change in serum biomarkers for 34 subjects who completed the trial

BiomarkerMedian prestudyMedian poststudyMedian absolute changeMedian relative changeP (Wilcoxon)
ELISA methodology
 High-molecular weight adiponectin, μg/mL5.85.7−0.09−2%0.73
 hsCRP, μg/mL1.41.2−0.2−23%0.16
 IGFI, nmol/L18.516.70.43%0.98
 IGFBP3, nmol/L116110−4−4%0.080
 IGF-1:IGFBP3 ratio0.160.170.015%0.20
 SHBG, nmol/L (with estradiol)114.5112.62.55%0.33
 Estradiol, pg/mL73.377.4−10.5−11%0.13
 Estradiol, pmol/L0.270.29−0.4−11%
 Bioavailable estradiol, pmol/L2.713.08−0.31−15%0.13
 Progesterone, ng/mL0.900.97−0.03−4%0.98
 Progesterone, nmol/L2.93.1−0.1−4%
 SHBG, nmol/L (with testosterone)99.4105.50.61%0.86
 Testosterone, ng/mL0.550.46−0.03−5%0.38
 Testosterone, nmol/L1.881.60−0.11−5%
 Bioavailable testosterone, pmol/L16.616.5−0.12−2%0.38
Luminex methodology
 Adiponectin, μg/mL17.018.4−1.3−8%0.44
 Leptin, ng/mL12.312.31.29.4%0.67
 Adipo:Leptin ratio1,1701,559−36−6%0.37
 HGF, pg/mL264240−17−8%0.74
 Insulin, pg/mL168140−18−9%0.22
 MCP-1, pg/mL179166−7−5%0.21
 NGF, pg/mL5.95.5−0.3−6%0.18
 PAI-1, ng/mL30.332.1−0.8−3%0.97
 Resistin, ng/mL23.424.5−0.8−4%0.54
 TNF-α, pg/mL2.72.80.00%0.88
Assessment of insulin resistance
 Glucose, mg/dL95.093.0−2.5−3%0.075
 Immunoreactive Insulin, μIU/ml5.34.70.00%0.55
 Pro-Insulin, pmol/L8.79.20.22%0.89
 HOMA2 %B61.266.75.19%0.13
 HOMA2 %S142.6160.3−0.10%0.78
 HOMA2 IR0.70.60.00%0.32